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Emerging evidence suggests that omega (n)-3 PUFA and their metabolites improve maternal and
neonatal health outcomes by modifying gestation length, and reducing the recurrence of pre-term de-
livery. N-3 PUFA has been associated with prolonged gestation and increased birth dimensions such as
birth weight and head circumference. However, mothers giving birth to larger babies are at an increased
risk of having dysfunctional labour, genital tract laceration, and delivery via caesarean section. Likewise,
high infant weight at birth has been linked to several metabolic and cardiovascular disorders in the
offspring. Prolonged gestation also leads to reduced placental function which has been implicated in fetal
distress, and perinatal death. Till date, the mechanism through which high n-3 PUFA intake during
pregnancy increases gestation length and birth weight is vaguely understood. Early and later stages of
pregnancy is characterised by increased production of pro-inﬂammatory cytokines which are required
for pregnancy establishment and labour regulation respectively. Conversely, mid-stage of pregnancy
requires anti-inﬂammatory cytokines necessary for uterine quiescence, pregnancy maintenance and
optimal fetal growth. Apparently, changes in the proﬁles of local cytokines in the uterus during different
stages of pregnancy have a profound effect on pregnancy progression. This review focuses on the intake
of n-3 and n-6 PUFA during pregnancy and the impact it has on gestation length and infant weight at
birth, with a particular emphasis on the expression of inﬂammatory cytokines required for timely
pregnancy establishment (embryo reception and implantation) and labour induction. It is concluded that
an appropriate dose of n-3 and n-6 PUFA needs to be established during different stages of pregnancy.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Maternal diet is critical for a successful pregnancy establish-
ment, as well as fetal health outcomes [1,2]. Nutrition during
pregnancy programs set points for metabolic and physiologicalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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adult life [3e5]. The hypothesis that early life dietary insults in utero
increases the vulnerability of the offspring to developing several
pathological conditions is now unequivocally accepted [3,6].
Several studies have now established that the quantity and quality
of dietary fats consumed during pregnancy have profound health
implication during and after pregnancy [7,8]. Omega (n)-6 and n-3
polyunsaturated fatty acids (PUFA), the essential fatty acids [9], play
critical roles during fetal growth and development [8,10e12].
However, the mean n-3 PUFA intake of about 90% of Canadian
women is only 82 mg per day, which is far below the recommen-
dation of the International Society for the Study of Fatty Acids and
Lipids for North Americans (300mg/day) [13]. Dietary shift over the
years toWestern diet has caused a drastic change in the ratio of n-6
to n-3 fatty acids from about 1e2:1 in the Paleolithic diet (hunter
gatherer's diet) to about 20e30:1 [14]. This transition has been
found to promote the pathogenesis of several diseases [15]. Meta-
bolism of n-3 PUFA such as docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA) produce anti-inﬂammatory lipids
mediators which have been shown to reduce the risks of speciﬁc
clinical endpoints [16,17], while n-6 PUFA are generally considered
inﬂammatory in nature [18].
DHA is important in the overall fetal growth, as well as the
development of vital organs such as the brain and eyes [11,12]. As
such, an inadequate intake of DHA during pregnancy has been
associated with impaired cognitive functions and visual acuity in
the offspring [19]. Besides, other spectrum of evidence has shown
that n-3 PUFA supplementation during pregnancy reduces the risk
of pre-term birth (PTB), especially in high risk pregnancies [20e23].
Women consuming diets high in n-3 PUFA during pregnancy were
observed to have longer gestational length, and consequently, high
birth dimensions such as birth length, birth weight and head
circumference [22e33]. To identify appropriate studies on the ef-
fect of n-3 PUFA on pregnancy establishments and outcomes,
MEDLINE (PubMed) and Web of Science databases were searched
thoroughly using the following keywords; pregnancy, implanta-
tion, labour, cytokines, polyunsaturated fatty acids, and birth out-
comes. Adequately controlled studies (Randomized controlled
clinical trials), as well as prospective cohort studies assessing the
effect of n-3 PUFA intake during pregnancy on pregnancy duration
and outcomes in women of reproductive age were considered for
this review. Studies limited by subject number (<50 subjects) were
excluded, while studies published in English language, between
1985 and 2015 were included.
Women supplemented with high n-3 PUFA had their gestation
length extended by 6 days [34] and 8.3 days longer in high risk
pregnancies [35]. Prolonged gestation and high birth weight,
however, has been associated with several maternal, fetal and
neonatal health risks. Mothers giving birth to larger babies are at an
increased risk of having prolong labour, excessive bleeding, and
genital tract laceration due to baby having head or shoulder too big
to pass through the mother's pelvis, thereby resulting in
instrument-assisted delivery, or caesarean delivery [36]. High birth
weight has also been associated with childhood obesity [37], dia-
betes [38], and metabolic syndrome [39]. Equally, prolonged
pregnancy (post-term) increases emotional stress in mothers [40].
Prolonged pregnancy also result in reduced placental function, and
this increases the risk of fetal distress and ultimately perinatal
death due to low supply of nutrients and oxygen to the developing
fetus [41]. These observations emphasize on the possible negative
impact of consuming high n-3 PUFA diet during pregnancy due to
gestational length modiﬁcation, however, the dosage and mecha-
nism/s through which n-3 PUFA increases gestation length and
birth weight is yet to be clearly elucidated. Pregnancy was initially
thought to be a single event characterised by either pro-inﬂammatory or anti-inﬂammatory molecules [42]. However,
subsequent studies disapproved the pro- or anti-inﬂammatory
molecules dichotomy during pregnancy.
Pregnancy is made up of three (3) distinct biological phases with
each phase having different classes of predominating pro- or anti-
inﬂammatory mediators [43]. Early and later stages of pregnancy
are characterised by an increased production of pro-inﬂammatory
cytokines which are required for timely pregnancy establishment
[44,45] and labour stimulation respectively [43,46]. In contrast, the
mid-stage requires anti-inﬂammatory cytokines necessary for
uterine quiescence, and optimum fetal growth [43]. This review
explores the properties of n-3 PUFA on the regulation of uterine
expression of cytokines required for timely and successful preg-
nancy establishment and labour stimulation. The focus will be on
the plausible consequences of altering pro-inﬂammatory cytokines
signalling on gestation length and infant weight at birth.
2. Metabolism and transport of essential PUFA during
pregnancy
Humans lack the enzyme required for the insertion of a cis
double bond at 3rd and 6th carbon of n-3 and n-6 PUFA respec-
tively, thus making these fatty acids essential [47]. The simplest
form of n-3 (alpha-linolenic acid; ALA) and n-6 PUFA (linoleic acid;
LA) must therefore be obtained from the diet. Once consumed,
longer chain PUFA, such as arachidonic acid (AA), can be synthe-
sized endogenously from LA, while EPA and DHA are produced from
ALA through series of desaturation and elongation processes [48]
(Fig. 1). Studies using stable radiolabelled fatty acids have shown
that the rate of metabolism of essential PUFA is sex speciﬁc; sex
hormones may inﬂuence the enzymatic synthesis of longer chain
fatty acids as the metabolism of ALA to DHA was observed to be
higher and faster in women than men [49,50]. In men, the con-
version rate of ALA to EPA is about 8%, while ALA to DHA is between
0 and 4%. On the other hand, about 21% and 9% ALA is converted to
EPA and DHA respectively in women [49].
DHA is very important for healthy brain and eyes (retina)
development, as well as overall fetal growth during pregnancy
[11,12]. Brain has the largest amount of lipids (60% dry weight),
compared to other organs in the body [51]. DHA constitute about
10e15% of total fatty acids in the brain, and this represents more
than 97% of total n-3 PUFA [52,53]. It has been shown that there is
acceleration of fetal brain growth during the second trimester [8];
perhaps, this is the most critical stage for DHA supplementation.
However, it has been shown that the accumulation of DHA in the
brain is most rapid during the third trimester of pregnancy and the
ﬁrst year after birth [54,55]. Fetus accrues up to 70mg DHA per day
during the last trimester, speciﬁcally in the brain, and white adi-
pose tissues [56], demonstrating the signiﬁcance of maternal DHA
status on fetal health. Interestingly, studies have shown that
maternal DHA level is usually low during the last trimester, which
explains a higher rate of transfer of DHA to the fetus [57]. At the
same time, lowmaternal n-3 PUFA levels at the last trimester could
be an in-built regulatory mechanism to enhance the synthesis of
the pro-inﬂammatory molecules required for labour induction.
Nonetheless, a deﬁcit of n-3 PUFA during pregnancy results in
impaired cognitive and physiological functions in rats [58], which
has been suggested to be irreversible by postnatal supplementation
[59].
Evidence suggests that the pathway for the synthesis of longer
chain PUFA becomes upregulated and highly efﬁcient during
pregnancy so as to meet both maternal and fetal requirement [60].
The ALA to DHA conversion pathway is complimented by increased
mobilization of accumulated DHA reserves in the maternal tissues
prior to conception [50], and also by supplementing maternal diet
Fig. 1. Elongation and desaturation of essential polyunsaturated fatty acids. AA: Arachidonic acid; ALA: Alpha linolenic acid; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic
acid; LA: Linoleic acid; PUFA: Polyunsaturated fatty acid.
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undergoing frozen embryo transfer reported an increase in the
mobilization of maternal DHA at early stage of pregnancy prior to
neural tube closure [61], and the concentration of DHA in maternal
plasma doubles in twin pregnancies compared to singleton preg-
nancies. These studies emphasize the importance of maternal
metabolic response during pregnancy on fetal development,
especially in the closure of neural tube. As such, DHA intake of
women before and during pregnancy may have a great impact on
the amount of DHA available for fetal use. In addition to the
increased maternal metabolic capacity for DHA synthesis during
pregnancy, the rate of transfer across the placenta also plays a
critical role in regulating the amount of DHA in fetal tissues [62].
Pre-formed longer chain PUFA such as DHA and AA from maternal
circulation are selectively and preferentially transferred across the
placenta to the fetus during pregnancy [57,62]. Fetal accumulation
of n-3 PUFA in utero is predominantly regulated by maternal n-3
PUFA status and the placental function [62].
Development of the placenta is a remarkably coordinated
physiological adaptation required for materno-fetal interaction
during pregnancy. The placental functions are precisely regulated
to ensure efﬁcient and timely exchange of nutrient, oxygen, and
waste between maternal circulation and the growing fetus.Nutrients and oxygen transfer during pregnancy is further
enhanced by increased blood ﬂow to the placenta via dilated blood
vessels [63]. In addition, the functional characteristics of the
placenta changes in order to accommodate the metabolic require-
ment of the developing fetus, and this include preferential transfer
of essential fatty acids during the last trimester of pregnancy
[62,63]. Translocation of essential fatty acids across the placenta
occur via passive diffusion or throughmembrane protein-mediated
mechanism [62,64] (Fig. 2). Physiologically, the protein-mediated
transportation of fatty acids has been shown to be quantitatively
more important than passive diffusion [62]. Several membrane
located proteins have been identiﬁed to be involved in the trans-
port of longer chain n-3 PUFA across the placenta, and these include
the highly glycosylated fatty acid translocase (FAT), also referred to
as cluster of differentiation-36 (CD36); placental membrane fatty
acid binding protein (p-FABPpm); and the fatty acid transport
proteins (FATP) [62]. Furthermore, transfer of long chain PUFA to
the fetus is ampliﬁed by the activity of placental lipoprotein lipase
(LPL), phospholipase A2 (PLA2), intracellular lipases, and tri-
acylglycerol hydroxylase [65,66]. LPL and PLA2 hydrolyse maternal
plasma lipoproteins and phospholipids, resulting in the liberation
of PUFA, which are subsequently transported to the fetus. Lipolytic
activity increases dramatically during the third trimester [67], and
Fig. 2. Transport of essential PUFA during fetal development (Adapted from Duttaroy, 2009) [62]. AA: Arachidonic acid; DHA: Docosahexaenoic acid; FAT: Fatty acid translocase;
FABP: Fatty acid binding proteins; FATP: Fatty acid transport protein; LDL: Low density lipoprotein; LPL: Lipoprotein lipase; PLA2: Phospholipase A2; p-FABPpm: Placental plasma-
membrane fatty acid binding protein; VLDL: Very low density lipoprotein.
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adequate delivery of essential longer chain PUFA via the placenta. A
deﬁcit in essential longer chain PUFA supply due to placental
dysfunction or inadequate perinatal consumption has been attrib-
uted to speciﬁc adverse pregnancy outcomes [68].3. Omega-3 PUFA intake and pregnancy outcomes
3.1. Effect of omega-3 PUFA intake on the risk of pre-term birth
(PTB)
PTB is a major recurrent problem in obstetrics which accounted
for about 35% of all infant deaths in the United States in 2010 [69].
PTB is currently the leading cause of developmental disabilities
[70], as well as neonatal morbidity and mortality in Canada and
worldwide [71]. Data fromWorld Health Organization (WHO, 2015)
[72] revealed that an estimated 15 million babies are born prema-
ture every year across the globe. PTB constitutes an economic
burden of about $587.1 million per year in Canada [71]. The path-
ophysiology of PTB is yet to be completely understood, however,
several studies have reported a signiﬁcant positive association be-
tween maternal n-3 PUFA intake and PTB. Earliest population-wide
study reported that women in Faroe Island consuming high
amounts of marine foods (rich source of n-3 PUFA) had a very low
risk of birth before 37th week of pregnancy [73]. Subsequent
studies further conﬁrmed the positive effect of consuming n-3
PUFA on PTB (Table 1).A prospective cohort study conducted in Denmark revealed that
a low intake of n-3 PUFA is a risk factor for PTB; the incidence of PTB
was higher in women who never ate ﬁsh compared to those who
consumed ﬁsh at least once per week [21]. Furthermore, data from
a 50-year-old controlled ﬁsh supplementation trial conducted in
London showed a 20.4% reduction in PTB [75]. More recent inter-
vention studies show that the hazard risk of spontaneous PTB
reduced by about 39% in women who consume moderate amount
of ﬁsh [76,77]. Fish oil intake was also observed to reduce the
recurrence of PTB from about 33% to 21% in women who received
ﬁsh oil supplementation (2.7 g/d of EPA and DHA) at 20 weeks
gestation, or 6.1 g/d of EPA and DHA at about 33 weeks gestation
[27]. The beneﬁcial effects of consuming n-3 PUFA, relating to
reduction in the risk of PTB during pregnancy, has been attributed
to its involvement in gestation length modulation [78].3.2. Effects of n-3 PUFA on gestation length and infant size at birth
Studies have suggested that the intake of longer chain n-3 PUFA
can improve pregnancy outcomes [20,22,24,28,31]. Data from
intervention trials and observational studies have suggested a
positive association between intake of n-3 PUFA during pregnancy
and the gestation length, and consequently the weight of infants at
birth [73,75,78]. Of interest is the observation that about 1% relative
increase in cord serum phospholipid DHA in Faroe Island women
was associated with approximately 1.5 days increase in gestation
length [79]. Likewise, high intake of marine fat slightly reduced the
Table 1
Omega-3 polyunsaturated fatty acids and pre-term delivery.
Intervention Outcome(s) in the treatment group Reference(s)
Fish oil 2.7 g and 6.1 g EPA þ DHA (20 weeks gestation until delivery until delivery) Fish oil reduced recurrence risk of pre-term delivery from 33% to
21%.
[27]
Fish and ﬁsh oil intake (at least once per week) Reduced incidence of preterm delivery from 7.1% to 1.9% [21]
DHA capsules, 600 mg/day (<20 weeks until delivery) Lower risk of PTB [30]
DHA supplementation; up to 600 mg/day (16e20 weeks of gestation) Reduced the rate of early PTB signiﬁcantly [74]
Fish oil consumption (week 20 until delivery) 20.4% reduction in risk of early delivery [75]
Fish oil capsule containing 2.7 g n-3 PUFA at week 20 or 6.3 g n-3 PUFA at week 33 until
delivery
44% reduction in the hazard rate of spontaneous delivery [76]
DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acis; PUFA: Polyunsaturated fatty acid; PTB: Pre-term birth.
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compared with Danish women [73,78]. A randomized controlled
trial suggested that ﬁsh oil supplementation may alter pregnancy
duration by inhibiting the production of prostaglandins which play
key roles in labour induction at term, thereby increasing the
gestation period [26].
Randomized controlled clinical trials on the effects of n-3 PUFA
on pregnancy duration and birth weight have produced consistent
results over years (Table 2). These intervention studies showed that
marine oil supplementation increases the risk of prolonged preg-
nancy and high birth dimensions such as head circumference, birth
length and birth weight. Women supplemented with longer chain
n-3 PUFA from ﬁsh oil had a signiﬁcantly longer gestation period;
average of 4 days for most pregnancy and higher in high risk
pregnancies [22,25,26,28e30]. Danish womenwho received ﬁsh oil
supplements during third trimester of pregnancy (1.13 g DHA/day
and 1.57 g EPA/day) had higher birth weight and increased gesta-
tion period (about 4 days) compared to the control group [25].
Similar outcomes have also been observed in epidemiological and
cohort studies where mothers consumed n-3 PUFA before preg-
nancy establishment and throughout the gestation period
[24,32,73]. A randomized, double-blind, controlled study has also
revealed that dietary supplementation with DHA-enriched eggs
(about 133 mg/egg/day) during the last trimester increases gesta-
tion length by approximately 6 days [34]; This was a population-
based study (n ¼ 350), in which 83% of subjects completed the
study. Also, pregnant women who received ﬁsh oil (about 323 mg/
day containing approx. 100 mg DHA) or sunﬂower oil, from 15
weeks gestation until delivery, showed a slightly increased gesta-
tion length in infants with higher umbilical cord plasma DHA in the
DHA-supplemented group compared to the placebo group; how-
ever, this observation did not reach statistical signiﬁcance [81]. It
appears that ﬁsh oil containing 2.7 g omega-3 fatty acids
(EPA þ DHA)/day from 30th week of pregnancy until parturitionTable 2
Effects of omega-3 polyunsaturated fatty acids on gestation length and birth weight.
Intervention Outcome(s) in th
Fish oil containing 2.7 g n-3 fatty acids (EPA þ DHA)/day (30 weeks
gestation until delivery)
Prolonged gesta
Increased birthw
DHA-enriched eggs, 133 mg per day (24e28 weeks gestation until
delivery)
Prolonged gesta
Birth weight als
Seafood intake during pregnancy Increase in gesta
No association w
Maternal DHA intake (<16 weeks until delivery) Higher birth we
Gestation length
323 mg ﬁsh oil containing about 100 mg DHA per day from 15 weeks
gestation until delivery
Increased gestat
No signiﬁcant ef
Maternal fatty ﬁsh consumption (about 3.8 g day) Reduction in the
DHA supplementation; up to 600 mg per day (16e20 weeks of
gestation)
1.6 days increas
length, or head
DHA: Docosahexaenoic acid; EPA: Eicosapantaenoic acid; PTB: Pre-term birth.produced the most signiﬁcant increase in infant weight at birth by
107 g, while consuming DHA (33 or 133 mg) from eggs at 24th and
28th week of pregnancy until parturition increased gestation
length the most by 6.0 ± 2.3 days (P ¼ 0.009) in the higher DHA
group. The observed variations in the gestation length, as well as
theweight of the infants at birth can clearly be attributed to varying
doses of n-3 PUFA during intervention, timing of the intervention,
as well as the duration of the treatment. However, the ﬁndings
published to date do not provide evidence towards an appropriate
dose of n-3 PUFA and/or the time of intervention to cause an in-
crease in gestation time period or birth weight.
Of keen interest in the intervention studies is the observation
that n-3 PUFA treatment were generally administered after the
pregnancy had been established (Table 2). Data from observational
studies, where mothers consumed high amount of n-3 PUFA prior
to conception, revealed a signiﬁcantly higher infant weight at birth.
Corrected average birth weight among Faroese woman was
3610 ± 603 g, and the frequency of having new born infants heavier
than 4.5 kg was 3 (three) times higher than Denmark where n-3
PUFA consumption was very low [73]. It can therefore be argued
that n-3 PUFA supplementation at the early stage of pregnancy may
have a signiﬁcant inﬂuence on gestation length and other preg-
nancy outcomes; perhaps by regulating pregnancy establishment
activities, leading to gestation length prolongation and conse-
quently high infant weight at birth. On the other hand, a few studies
have shown that n-3 PUFA has neither beneﬁcial nor harmful ef-
fects on gestation length, infant weight at birth and other preg-
nancy outcomes [82,83]. In general, it appears that a diet high in n-
3 PUFA may inﬂuence various activities involved in successful and
timely pregnancy establishment, and requires a more robust and
mechanistic investigation. The mechanism through which n-3
PUFA inﬂuences gestation length is perhaps associated with their
effect on regulating the balance of pro- and anti-inﬂammatory
cytokines.e treatment group Reference(s)
tion by about an average of 4 days.
eight by 107 g
[25,26]
tion by 6 days.
o increased but did not reach statistical signiﬁcance (P ¼ 0.06)
[34]
tional length of 0.02 week (95%CI: 0.002 to 0.035).
as observed with birthweight.
[80]
ight and head circumference
was not determined
[31]
ion length in infants with higher umbilical cord plasma DHA
fect on birth weight, length and head circumference
[81]
risk of having babies with low birth weight [32]
e in gestational length. No signiﬁcant effects on birth weight, birth
circumference.
[74]
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Pregnancy has been clearly divided into three (3) distinct stages
(trimesters), and each of these stages is characterized by different
proportions of pro- and anti-inﬂammatory molecules [43]. It has
been shown that the ﬁrst trimester of pregnancy is primarily
characterised by increased production of pro-inﬂammatory bio-
molecules such as the cytokines as they are required for embryo
reception, successful implantation, and co-ordination of fetal-
maternal cross-talk [43,44,84]. Likewise, activities involving cervi-
cal ripening and uterine contraction regulation at term are medi-
ated by local pro-inﬂammatory signals in the maternal uterine
tissues [43,85]. In contrast, the second stage of pregnancy requires
high levels of anti-inﬂammatory molecules necessary for uterine
quiescence and optimum fetal development. Implantation is a
critical stage in pregnancy establishment involving complex
sequence of signalling cascades required for a harmonized dialogue
between a functional blastocyst and the endometrium, and it is
largely mediated by pro-inﬂammatory cytokines [43,86].
Embryonic implantation occurs about 9 days after fertilization
in human and this process involves several cytokines such as in-
terleukins (IL), leukemia inhibitory factor (LIF), interferon (IFN)-g,
tumor necrosis factor (TNF)-a, and migration inhibitory factor
(MIF). TNFa regulates the synthesis and activity of matrix metal-
loproteinase (MMP-2 and MMP-9) which is associated with the
invasive phase of blastocysts implantation [87,88]. IFNg is involved
in the initiation of endometrial vasculature remodelling, mainte-
nance of implantation sites, and the decidua (maternal component
of the placenta) [89]. Prior to embryo implantation, activities
involving endometrial function and embryo reception regulation
has been shown to be mediated by cytokines such as TNF-a [87,88],
IL-1 [43,44,90,91], IL-6 [43,44,92], IL-15 [90,93,94], IL-18 [94,95],
LIF [44,96,97], IFN-g and MIF [97e100] (Table 3).
LIF was the ﬁrst cytokine shown to be very critical for implan-
tation in mice as it was found to be very abundant at the implan-
tation site [101]. Hence, blastocyst implantation was suggested to
be strictly dependent on maternal expression of LIF. However,
several other studies argued that MIF plays a major role as a pro-
inﬂammatory cytokine mediator during pregnancy establishment
as it can either directly or indirectly regulate the synthesis of
several other pro-inﬂammatory cytokines including TNF-a, IL-10
and IL-12 [102]. MIF has been found to be highly expressed in the
oviduct, ovaries and uterus of mouse at early pregnancy [100].
Protein and mRNA expression of MIF was reported to be higher atTable 3
Roles of pro-inﬂammatory cytokines in pregnancy establishment.
Cytokines Production site Roles in implantation
TNFa Peri-implantation endometrium Regulates the synthesis and activity of m
IFNg Uterus NK cells and trophoblasts Initiates endometrial vasculature remode
of the decidua
LIF Stroma cells and endometrial
epithelium
Regulate the adhesion and invasion of u
IL-1 Endometrium and blastocyst Stimulate the secretion of other cytokine
play important role in embryo implantat
IL-6 Embryo and uterus (stroma cells
and endometrial epithelium)
Regulates endometrial function and synt
implantation sites and decidua formatio
IL-15 Decidua and endometrium Involved in implantation and decidualiza
IL-18 Stroma cells and endometrial
epithelium
Regulate the growth of NK cells in the u
MIF Endometrial tissues and decidua Induces the expression of other cytokine
and activity of MMPs, and reduces the c
dependent manner
IFNg: Interferon gamma; IL: Interleukine; MIF: Macrophage Migration Inhibitory Facto
Uterine natural killer cells.early stages of gestation in the placenta, amniotic ﬂuid and
maternal serum [103,104]. The concentration of MIF declines as the
pregnancy progresses, with most signiﬁcant changes in the late
ﬁrst trimester [105]. This evidence further supports the roles of MIF
in important cellular functions leading to endometrial receptivity,
successful embryonic implantation and timely placental formation.
As expected, mice treated with MIF were shown to have enhanced
embryo implantation compared to the untreated mice [98]. Like-
wise, intraperitoneal injection of IL-1 receptor antagonist into
pregnant mice few days before implantation was observed to
interfere with embryonic interaction with the endometrial tissue,
thereby causing implantation failure [106]. IL-1 has also been
shown to be involved in the stimulation of several other cytokines
such as TNF-a, LIF, IL-6, and IL-8 [90]. IL-1 has been found in human
trophoblast, fallopian tube, and endometrium [107,108], and the
presence of its bioactive ligands (IL-1a and IL-1b) in human embryo
culture medium has been shown to correlate with the implantation
rates of patients undergoing in vitro fertilization-embryo transfer
[109]. Other molecular mediators involved in the embryo implan-
tation and pregnancy establishment are growth factors, adhesion
molecules, prostaglandins, hormones and lipids [43e45,86].
As pregnancy progresses towards the second trimester, the
proﬁle of cytokines shifts towards less inﬂammatory/anti-
inﬂammatory cytokines [43]. Studies have shown that the expres-
sion of anti-inﬂammatory cytokines such as IL-4 and IL-10 plays an
important role in the resolution of inﬂammation during pregnancy,
especially at the second trimester [43,110]. Optimally functioning
inﬂammation resolution system during pregnancy is essentially
required to regulate series of complex processes that could
degenerate into persistent inﬂammation and hence, complications
during pregnancy. PTB has been associated with the induction of
prostaglandin synthesis before term via excessive production of
pro-inﬂammatory cytokines like TNF-a, IL-6, and IL-1b which
triggers pre-term labour [111]. Also, infusion of IL-6 and TNF-a has
been shown to produce symptoms of pre-eclampsia in rat [112,113].
However, other studies have associated IL-10 deﬁciency with the
onset of hypoxia-induced pre-eclampsia features such as protein-
uria, hypertension and renal pathology in mice [114]. As such,
administration of recombinant IL-10 was observed to reverse fea-
tures of pre-eclampsia in IL-10 knock out pregnant mice [114]. IL-10
has been shown to peak on gestation day 12 in mice, which
represent second trimester [115]. Inhibition of IL-10 during preg-
nancy has been shown to result in neonatal growth retardation
[116], while administration of exogenous IL-10 has been shown toReference(s)
atrix metalloproteinase (MMP-2 and MMP-9) [87 e Human endometrial
cells, in vitro]
lling, angiogenesis at implantation sites, maintenance [89 e Mice]
terus by embryo [96 e Human endometrial
cells, in vitro]
s (IL-6, LIF, and TNFa), regulates uterine receptivity,
ion and decidualization
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Although IL-4 and IL-10 has been suggested not to be involved in
fetal or neonatal survival in mice [118], the roles of anti-
inﬂammatory cytokines in inﬂammation resolution during preg-
nancy cannot be overemphasized.
At near term, cytokine proﬁle has been characterized to align
towards increased production of pro-inﬂammatory cytokines [43].
Pro-inﬂammatory cytokines have been suggested to play vital roles
in the coordination of several processes leading to labour; these
include cervical ripening, and uterine contraction [43]. The exact
mechanism through which labour is regulated by pro-
inﬂammatory cytokines is vaguely understood. An increased pro-
duction of major pro-inﬂammatory cytokines such as TNFa, IL-1b,
and IL-6 in the uterus has been implicated in the stimulation of
phospholipid metabolism pathways, release of arachidonic acid, as
well as serving as precursors for the production of prostaglandins
which play key role in cervical dilation and myometrial contraction
during labour [119]. Furthermore, IL-1b and IL-8 have been found at
increased levels in the myometrium and choriodecidua at last
trimester of pregnancy [120]. Clearly, cytokine balance during
pregnancy is very important for successful pregnancy establish-
ment, and maintenance. As such, dysregulation in pro- and anti-
inﬂammatory cytokines could result in detrimental pregnancy
outcomes. Plethora of evidence have shown that longer chain n-3
PUFA could alter the production, as well as the activities of pro- and
anti-inﬂammatory cytokines [121], which may have a profound
effect on pregnancy establishment and outcomes.
5. Omega-3 PUFA and cytokine regulation during pregnancy
Metabolism of n-3 PUFA gives rise to anti-inﬂammatory mole-
cules [122]. Interestingly, the same group of enzymes are required
for the metabolism of n-3 and n-6 PUFA (Fig. 1), and as such, the
anti-inﬂammatory properties of n-3 PUFA is partly mediated by
suppressing or inhibiting the downstream production of pro-
inﬂammatory molecules from n-6 PUFA metabolism [123]. An
established mechanism for the anti-inﬂammatory effect of n-3
PUFA is by inhibiting the production of nuclear factor-kappaB (NF-
kB), which is a transcription factor for a number of pro-
inﬂammatory cytokines such as TNF-a, and IL [122]. Likewise, it
has been shown that n-3 PUFA could directly reduce the gene
expression of IL-6, and IL-1b [124]. Studies have shown that sup-
plementing maternal diet with n-3 PUFA (2 g EPA þ DHA per day)
results in signiﬁcant reduction in the production of IL-1, IL-6, and
TNF-a by mononuclear cells [125]. Also, ﬁsh oil feeding reduces
ex vivo production of IL-1b, IL-6, and TNF-a by macrophages in
rodents [126]. Similar results were also obtained in cell culture
studies as EPA and DHA was observed to supress the production of
pro-inﬂammatory cytokines by macrophages and endothelial cells
[127,128]. However, DHA has been shown to be more effective than
EPA in reducing plasma TNF-a concentrations, 35% and 20% for DHA
and EPA respectively [129].
As explained earlier, the complexity of pregnancy establish-
ment, maintenance and labour is exempliﬁed by a number of cy-
tokines and other factors playing speciﬁc roles in this process as the
pregnancy progresses [43,84]. As such, n-3 PUFA as a potent pre-
cursor for inﬂammation resolving biomolecules may be inﬂuencing
gestation length by disturbing the normal expression and activities
of pro-inﬂammatory cytokines that are required at different stages
of pregnancy as depicted in Fig. 3. However, there are no studies to
date to show the effect of n-3 PUFA at each stage of pregnancy on
the outcome of pregnancy establishment and outcome. Consuming
high amounts of n-3 PUFA prior to embryo implantation may
downregulate the expression, and the activities of key pro-
inﬂammatory cytokines [130], such as IL-1, IL-6, MIF, LIF, andTNF-a that play key regulatory roles in the receptivity of the
endometrium, as well as the apposition, adhesion and invasion of
the uterine wall by the blastocyst. This may result in the elongation
of time required for pregnancy establishment. Thus, understanding
the effect of n-3 PUFA at this stage of pregnancy may provide
additional plausible insight into themechanism/s throughwhich n-
3 PUFA elongates gestation length.
Available data only suggest that n-3 PUFA prolongs pregnancy
duration by suppressing the synthesis of prostaglandins required
for the induction of labour. The effects of prolonged gestation on
both maternal and fetal health has been well documented
[131e133]. From a paediatric perspective, increased gestational
period and birth weight could be viewed as a positive outcome.
However, prolonged gestation is a predisposing factor for a number
of obstetrical complications [132]. Maternal peri-partum compli-
cations has been shown to increase as pregnancy progresses
beyond 40 weeks of gestation [133]. The risk of perinatal death also
increases from 39th week of pregnancy with a more dramatic in-
crease after week 40 of pregnancy [131]. Major reason for increased
risk of perinatal death in post-term pregnancy has been attributed
to reduced placental function [41]. Thus, prolonged pregnancy is a
major challenge in obstetrics as it is difﬁcult to know when to
induce labour [134]. It is also challenging to distinguish between
those that will respond to labour induction and those that require
caesarean section [134]. More so, high infant weight at birth as a
consequence of prolonged gestation has been linked to childhood
obesity, as well as several metabolic and cardiovascular disorders in
the offspring. Higher birth weight was associated with higher risk
of child obesity (a risk of cardivascular diseases) in Australia in boys
and girls before and after adjusting for several socio-demographic
factors [37]. Likewise, it has been shown that metabolic syn-
drome was more prevalent in children born with larger birth
weight, thereby suggesting that hypertension and hyper-
triglyceridemia as better components for diagonising metabolic
syndrome in obese children [135]. As such, it is highly pertinent to
determine the dose of n-3 PUFA at different stages of pregnancy to
prevent detrimental pregnancy outcomes.
6. Conclusions
Supplementation of maternal diet with n-3 PUFA has been
shown to have a positive effect on fetal brain development and
reduction in the recurrence of PTB, especially in women with his-
tory of pre-term or low baseline n-3 PUFA intake (high risk popu-
lation). However, supplementation of maternal diet with high n-3
PUFA has been linked to prolonged gestation length and conse-
quently, high infant birth weight. The variation in gestation length
and birth weight of infants in mothers supplemented with n-3
PUFA during pregnancy can be attributed to dosage of the n-3
enriched diet as well as the timing and duration of intervention
during pregnancy. Plethora of adverse pregnancy outcomes
relating tomaternal and perinatal health have been associatedwith
prolonged gestation. Increased birth weights also have prognostic
potential for development of diseases at adult life. Most n-3 PUFA
intervention studies started at the second trimester of pregnancy,
thus the available data can only suggest that n-3 PUFA prolong
pregnancy by inﬂuencing the production of prostaglandins
involved in labour induction. There is paucity of evidence on the
effects of different dosage of n-3 and n-6 PUFA on the proﬁles of
local cytokines in the uterus at embryo reception, and pregnancy
establishment. Although a recent prospective, observational study
of human pregnancy by Meyer et al. [61] highlights the effect of
metabolic response in women undergoing frozen embryo transfer
at early pregnancy, more evidence is required to establish the
precise function of n-3 and n-6 PUFA at different stages of
Fig. 3. Possible effects of omega-3 PUFA on pregnancy establishment and outcomes. DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; IFN-g: Interferon gamma; IL:
Interleukin; LIF: Leukaemia inhibition factor; PUFA: Polyunsaturated fatty acids; TNF-a: Tumor necrosis factor alpha.
O.A. Akerele, S.K. Cheema / Journal of Nutrition & Intermediary Metabolism 5 (2016) 23e3330pregnancy with respect to pregnancy duration and birth di-
mensions. This review concludes that investigating the effect of
feeding different amount of n-3 and n-6 PUFA diet in animal model
on the local proﬁles (gene and protein expression) of inﬂammatory
cytokines in the uterinemilieu at different stages of pregnancy may
provide a better insight unto the mechanism/s through which n-3
PUFA modiﬁes gestation length and consequently, the weight of
infants at birth.
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